Study wrapper · #1222
Prospective changes in sleep quality and depressive symptom burden following initiation of GLP-1-based therapies in patients with obesity: a real-world study.
Editor's note
This is a small single-arm observational cohort with no comparison group, so regression to the mean and expectation effects cannot be excluded. The interesting detail is that response tracked baseline symptom severity rather than percentage weight loss, which argues against a purely weight-mediated explanation for the mood and sleep changes. Read the results as hypothesis-generating, and weigh them against the larger randomized mood-safety datasets rather than in place of them.
Plain-language abstract
Seventy-eight adults with obesity who started semaglutide or tirzepatide were followed for three months. Scores on a standard depression questionnaire and a standard sleep-quality questionnaire both fell substantially: the share of participants in the clinically significant depressive range dropped from about 55% to 12%, and the share with poor sleep dropped from about 55% to 17%. How much weight someone lost, and which of the two drugs they used, did not explain who improved.